Clinical Trial Update: Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update outlines dose-modified regimens combining emapalumab and ruxolitinib (E-Ru) for hemophagocytic lymphohistiocytosis in Phase 2 and Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophagocytic Lymphohistiocytosis

Drugs mentioned

• Gamifant (Emapalumab) (Emapalumab)
• Jakafi (Ruxolitinib) (Ruxolitinib)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Hemophagocytic Lymphohistiocytosis (HLH) | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING